Literature DB >> 18554574

Over-the-counter analgesics normalize blood glucose and body composition in mice fed a high fat diet.

Eric L Kendig1, Scott N Schneider, Deborah J Clegg, Mary Beth Genter, Howard G Shertzer.   

Abstract

Type 2 diabetes (noninsulin-dependent diabetes mellitus) develops from a pre-diabetic condition that is characterized by insulin resistance and glucose intolerance, and is exacerbated by obesity. In this study, we compared the ability of over-the-counter analgesic drugs (OTCAD) [acetaminophen (APAP); ibuprofen (IBU); naproxen (NAP); aspirin (ASA)], to protect against the development of a pre-diabetic state in mice fed a high fat diet. After 10 weeks on the high fat diet, mice had normal fasting blood glucose (FBG) levels, but exhibited impaired glucose tolerance. Treatment with 20 mg OTCADs/kg body weight improved glucose tolerance, with the order of efficacy, APAP=ASA>IBU, while NAP proved ineffective. Mice fed the high fat diet also exhibited increases in weight gain associated with an increase in body fat. OTCADs prevented in part this increase in body fat, in the order of efficacy, APAP=IBU>NAP=ASA. In isolated liver mitochondria, OTCADs inhibited succinate-dependent H2O2 production, while in white adipose tissue, APAP inhibited NADPH-oxidase mediated H2O2 production and lipid peroxidation. Thus, OTCADs diminish pro-oxidant processes that might otherwise exacerbate inflammation and a pre-diabetic state. We conclude that OTCADs, especially APAP and IBU, may be valuable tools to delay or prevent the development of type 2 diabetes from a pre-diabetic condition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18554574     DOI: 10.1016/j.bcp.2008.05.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Dietary whey protein lowers the risk for metabolic disease in mice fed a high-fat diet.

Authors:  Howard G Shertzer; Sally E Woods; Mansi Krishan; Mary Beth Genter; Kevin J Pearson
Journal:  J Nutr       Date:  2011-02-10       Impact factor: 4.798

2.  Low dose aspirin therapy decreases blood glucose levels but does not prevent type i diabetes-induced bone loss.

Authors:  Lindsay M Coe; Jeffery D Denison; Laura R McCabe
Journal:  Cell Physiol Biochem       Date:  2011-12-15

3.  Tetrahydroindenoindole inhibits the progression of diabetes in mice.

Authors:  Howard G Shertzer; Scott N Schneider; Eric L Kendig; Deborah J Clegg; David A D'Alessio; Elisabet Johansson; Mary Beth Genter
Journal:  Chem Biol Interact       Date:  2008-09-07       Impact factor: 5.192

Review 4.  The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Authors:  Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2013-05-30       Impact factor: 4.473

5.  Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel.

Authors:  Alison H Harrill; Pamela K Ross; Daniel M Gatti; David W Threadgill; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2009-05-06       Impact factor: 4.849

6.  Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.

Authors:  H G Shertzer; E L Kendig; H A Nasrallah; E Johansson; M B Genter
Journal:  Int J Obes (Lond)       Date:  2010-01-12       Impact factor: 5.095

7.  Etoricoxib treatment prevented body weight gain and ameliorated oxidative stress in the liver of high-fat diet-fed rats.

Authors:  Fariha Kabir; Kamrun Nahar; Md Mizanur Rahman; Fariha Mamun; Shoumen Lasker; Ferdous Khan; Tahmina Yasmin; Khondker Ayesha Akter; Nusrat Subhan; Md Ashraful Alam
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-08-11       Impact factor: 3.000

8.  Systematic drug repositioning based on clinical side-effects.

Authors:  Lun Yang; Pankaj Agarwal
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

9.  Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Authors:  Julie Massart; Karima Begriche; Caroline Moreau; Bernard Fromenty
Journal:  J Clin Transl Res       Date:  2017-02-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.